连接酶链反应结合荧光PCR法检测UGT1A1*28基因多态性

Abstract
Figure/Table
References
Related Citation (6)

Download: PDF (934 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To establish a detection method of UGT1A1*28 gene polymorphisms based on ligase chain reaction and fluorescent PCR(LCRPCR) and to evaluate efficacy of its clinical application. Methods: LCRPCR primers and probes were designed to detect the UGT1A1*28 gene polymorphisms, constructed standard products to evaluate sensitivity and specificity of this method. Peripheral blood samples of 50 colorectal cancer patients were detected and compared with data obtained by DNA sequencing.Results: The LCRPCR technique could be used to detect the TA6/6,TA7/7 and TA6/7 of UGT1A1*28 gene, the detection limit is 5 ng genome DNA, and the results of 50 clinical samples detected by this method were in full agreement with those of the DNA sequencing. Conclusion: LCRPCR method can accurately detect UGT1A1*28 gene polymorphisms.

Received: 21 December 2017

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2018/V28/I04/302

［1］Fujita K, Kubota Y, Ishida H, et al. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer\[J\]. World J Gastroenterol, 2015, 21(43):12234-12248.
［2］Wulaningsih W, Wardhana A, Watkins J, et al. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progressionfree survival in patients with advanced and/or metastatic colorectal cancer\[J\]. Cochrane Database Syst Rev, 2016,2:CD008593.
［3］Marangon E, Posocco B, Mazzega E, et al. Development and validation of a highperformance liquid chromatographytandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study\[J\]. PLoS One, 2015, 10(2):e0118194.
［4］Fujiwara Y, Minami H. An overview of the recent progress in irinotecan pharmacogenetics\[J\]. Pharmacogenomics, 2010, 11(3):391-406.
［5］Swami U, Goel S, Mani S. Therapeutic targeting of CPT11 induced diarrhea: a case for prophylaxis\[J\]. Curr Drug Targets, 2013, 14(7):777-797.
［6］Iyer L，King CD，Whitington PF，et al. Genetic predisposition to the metabolism of irinotecan（CPT11）. Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite（SN38）in human liver microsomes［J］.J Clin Invest，1998, 101（4）：847-854.
［7］Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with nonsmallcell lung cancer treated with irinotecan and cisplatin\[J\]. J Clin Oncol, 2006, 24(15):2237-2244.
［8］Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan\[J\]. J Clin Oncol, 2004, 22(8):1382-1388.
［9］Minami H, Sai K, Saeki M, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28\[J\]. Pharmacogenet Genomics, 2007, 17(7):497-504.
［10］Jannin A, Hennart B, Adenis A, et al. Lifethreatening irinotecaninduced toxicity in an adult patient with alveolar rhabdomyosarcoma: the role of a UGT1A1 polymorphism\[J\].Case Rep Oncol Med, 2017, 2017：2683478.
［11］MartinezBalibrea E , Abad A，MartinezCardus A ,et a1．UGT1A1 and TYM S genetic variants predict toxicity and response of colorectal cancer patients treated with firstline irinotecan and fluorouracil combination therapy\[J\]．Br J Cancer,2010,103(4):581-589.
［12］Okuyama Y, Hazama S, Nozawa H, et al. Prospective phase Ⅱ study of FOLFIR I for mCRC in Japan, including the analysis of UGT1A1*28/*6 polymorphisms\[J\]. Jpn J Clin Oncol, 2011, 41 (4):477-482.
［13］Jemal A, Siegel R, Ward E, et al. Cancer statistics\[J\]. CA Cancer J Clin, 2010, 60(5):277-300.
［14］GarciaCarbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins\[J\]. Clin Cancer Res, 2008, 8(3):641-661.
［15］Ulukan H, Swaan PW, Camptothecins: a review of their chemotherapeutic potential\[J\]. Drugs, 2002, 62(14):2039-2057.
［16］Wu X, Cokkinides V, Chen VW, et al. Associations of subsitespecific colorectal cancer incidence rates and stage of disease at diagnosis with countylevel poverty, by race and sex\[J\].Cancer,2006,107(5 Suppl):1121-1127.
［17］Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDPglucuronosyltransferases and their functional significance\[J\]. Toxicology, 2002,181-182: 453-456.
［18］Toffoli G, Cecchin E, Corona G, et al. Pharmacogenetics of irinotecan\[J\]. Curr Med Chem Anticancer Agents, 2003, 3(3):225-237.
［19］Beutler E, Gelbart T, Demina A. Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?\[J\]. Proc Natl Acad Sci USA, 1998, 95(14):8170-8174.
［20］Iyer L, Hall D, Das S, et al. Phenotypegenotype correlation of in vitro SN38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism\[J\]. Clin Pharmacol Ther, 1999, 65(5):576-582.
［21］Lauri A,Castiglioni B, Morabito S, et al. A tool based on Ligation Detection ReactionUniversal Array(LDRUA) for the characterization of VTEC by identification of virulenceassociated and serogroupspecific genes\[J\]. Mol Cell Probes, 2011, 25(1):35-43.
［22］Cariani A, Piano A, Consolandi C,et al. Detection and characterization of pathogenic vibrios in shellfish by a Ligation Detection ReactionUniversal Array approach\[J\]. Int J Food Microbiol,2012, 153(3):474-482.
［23］Datta S, Chatterjee S,Veer V.Recent advances in molecular diagnostics of hepatitis B virus［J］. World J Gastroenterol, 2014, 20(40):14615-14625.